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No evidence for major adverse events related to suspicion of Ebola in France,
2014e2015Table 1
Differential diagnosis and treatment delay attributable to suspicion of Ebola virus
disease (n ¼ 34)
Final diagnosis Diagnosis delay
attributable to EVD
suspicion, n (%)
Time from admission to
treatment initiation in
patients with delay
Malaria (n ¼ 10) 6 (60%) Median 2 hours (IQR, 0e10)
Community-acquired
pneumonia (n ¼ 3)
1 (33%) 2 hours
Gastroenteritis (n ¼ 3) 1 (33%) No treatment
Influenza-like illness (n ¼ 2) 0 No treatment
Pharyngitis (n ¼ 2) 1 (50%) No treatment
Miscellaneous (n ¼ 8)a 3 (37%) Pyelonephritis, 2 hours;
epilepsy, 3 hours;
influenza B, 51 hours
No final diagnosis,
fever resolved (n ¼ 6)
d d
IQR, interquartile range.
a Cellulitis, pyelonephritis, tuberculosis, HIV, salmonellosis, shigellosis, influenza B,
epilepsy (one patient each).Ebola virus is one of the most virulent human pathogens, mostly
transmitted by direct contact through broken skin ormucousmem-
branes with blood or blood-contaminated body fluids. The
2014e2015 Ebola virus disease (EVD) outbreak in West Africadby
far the largest in history to datedhas affectedmore than 28 500 pa-
tients and has killed more than 11 000. Outside of the outbreak
area, most countries implemented surveillance systems and spe-
cific rules for the management of suspect cases to ensure that no
secondary transmission occurs. Patients were classified as having
suspected EVD if they presented with fever within 21 days after
leaving an area at risk.
The importance of these precautions has been outlined by re-
ports of secondary transmission in Spain [1] and the United States
[2], when they were not adequately implemented. However, most
suspicion of EVD outside of the outbreak area turned out to be
more common infectious diseases, including malaria [3], and con-
cerns were raised that EVD suspicion could represent a loss of op-
portunity for early recognition and treatment of these potentially
life-threatening conditions. In addition, the use of Ebola personal
protective equipment has been shown to increase the risk of failure
for common medical procedures [4] and has psychological conse-
quences. We aimed to characterize the management of patients
suspected of EVD in France in 2014e2015, focusing on time elapsed
between EVD suspicion, and final diagnosis and treatment.
We performed a retrospective multicentre study of suspected
EVD cases managed in France from April 2014 to August 2015. In-
clusion criteria were fever, stay in an Ebola outbreak area within
21 days before fever onset and hospital admission for EVD suspi-
cion. The study was communicated to >700 physicians through
the mailing list of the French infectious diseases society (Societe
de Pathologie Infectieuse de Langue Française (SPILF)). Data were
extracted frommedical charts by physicians in charge and collected
on a standardized questionnaire, including timing of the following
events: admission, isolation start and discontinuation, diagnosis,
treatment and discharge. Diagnosis and treatment delays attribut-
able to EVD suspicion were estimated through review of medical
charts separately by at least two investigators (three, in case of
discrepancy). The study was approved by the French institute for
medical research and health institutional review board (approval
14-184).
Thirty-four patients fulfilled the inclusion criteria (19 male and
15 female subjects), with a median age of 33 years (interquartile
range (IQR), 26e43). They returned from Guinea (n ¼ 21), Nigeria
(n ¼ 4), Sierra Leone (n ¼ 3), Mali (n ¼ 3), Liberia (n ¼ 2) and Congo
(n ¼ 1). For seven patients, fever onset occurred in the outbreak
area; for the remaining 27, fever appeared in France, with a medianhttps://doi.org/10.1016/j.cmi.2017.09.004
1198-743X/© 2017 European Society of Clinical Microbiology and Infectious Diseases. Puduration of 1 day (IQR, 0e8) between return and fever onset. Other
symptoms included asthenia (n ¼ 27), headache (n ¼ 20), myalgia
(n¼ 18), abdominal pain (n¼ 10) and diarrhoea (n¼ 9). Themedian
duration between fever onset and admission was 1 day (IQR, 0e5),
and the median duration of patient isolationwith EVD specific pre-
cautions was 8 hours (IQR, 2e30). The final diagnosis was obtained
in 28 patients (82%), with a predominance of Plasmodium falcipa-
rum malaria (n ¼ 10; 29%). Retrospective review of medical files
suggested that for 12 patients (35%), EVD suspicion was associated
with a diagnosis delay (Table 1) for a median duration estimated at
3 hours (IQR, 2e36). The three cases with diagnosis delays esti-
mated to be >12 hours were viral gastroenteritis (36 hours), nonse-
vere malaria (50 hours) and influenza B (51 hours). All patients
survived.
We found that most patients with suspected EVD in France dur-
ing the 2014e2015 outbreak were finally diagnosed with other in-
fectious diseases, mostly malaria, and none had EVD. This is in line
with studies from the GeoSentinel Surveillance Network [3], with
malaria documented in 40% of ill travelers returning from Sierra
Leone, Liberia and Guinea. We estimated that a diagnosis delay
attributable to EVD suspicion occurred in 35% of patients, but
remained limited in most, with no major clinical consequence.
However, delayed diagnosis and treatment of malaria attributable
to EVD suspicion has been reported [5].
This study has limitations resulting from small sample size, po-
tential bias related to retrospective collection of data and subjectiveblished by Elsevier Ltd. All rights reserved.
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tres were required to enroll all cases of suspicious EVD, this case se-
ries may be more representative of the actual adverse events
related to the situation of suspicion of EVD compared to individual
case reports. Of note, a consensus on treatment delay was reached
through independent review of medical files by two investigators
in all cases.
In conclusion, we found no evidence of major adverse events
related to suspicion of EVD in France in 2014e2015, as most pa-
tients were adequately diagnosed and treated within the first hours
after admission. However, the risk of adverse events related to sus-
picion of such highly pathogenic virusesmust be taken into account
in the design of guidelines for screening and management of sus-
pect cases.
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